China Aoxing In-Licenses China Rights for Narcotic Drug Combo
ChinaBio Today submits:
China Aoxing (CAXG.OB) will collaborate with QRxPharma Limited (QRXPY.PK), a clinical stage Australian pharma, to develop MoxDuo®IV for the China market. MoxDuoIV is an IV formulation of QRxPharma’s patented morphine and oxycodone Dual-Opioid™ technology for the acute treatment of moderate to severe pain.
China Aoxing will fund development of MoxDuo®IV for the China market in exchange for exclusive marketing rights of the product in China. QRxPharma will retain ownership of MoxDuo®IV and may use the clinical work completed by China Aoxing in product registrations outside of China. Further financial details of the collaboration were not disclosed.